Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Feb;135(2):829-832.
doi: 10.1002/lary.31778. Epub 2024 Sep 19.

JAK-inhibitor Tofacitinib in Severe Laryngeal Sarcoidosis: A Case Report

Meryem Demir  1   2 , Vasileios Kouranos  1 , Kostadin Stoenchev  1 , Stephen R Durham  1   3 , Guy W Scadding  1   3 , Nilesh Morar  4 , Chadwan Al Yaghchi  5 , Guri S Sandhu  5 , Hesham Saleh  1   6
Affiliations
Case Reports

JAK-inhibitor Tofacitinib in Severe Laryngeal Sarcoidosis: A Case Report

Meryem Demir et al. Laryngoscope. 2025 Feb.

Abstract

Sarcoidosis is an inflammatory, non-caseating granulomatous multisystem disease associated with JAK-STAT (Janus kinases-signal transducer and activator of transcription proteins) pathway activation. We present a patient with severe multi-systemic sarcoidosis who showed marked improvement with tofacitinib with regards to pulmonary, cutaneous, nasal and laryngeal disease. Tofacitinib prevented critical laryngeal stenosis from progressing to tracheostomy, induced regression of cutaneous lesions and improved pulmonary function in this steroid-resistant and immunosuppressive intolerant case. This case report supports further the role of JAK-inhibitors in the treatment of systemic sarcoidosis. Laryngoscope, 135:829-832, 2025.

Keywords: JAK‐STAT; JAK‐inhibitor; laryngeal sarcoidosis; sarcoidosis; tofacitinib.

PubMed Disclaimer

References

BIBLIOGRAPHY

    1. Wang A, Singh K, Ibrahim W, King B, Damsky W. The promise of JAK inhibitors for treatment of sarcoidosis and other inflammatory disorders with macrophage activation. Rev Lit. 2020;93(1):187‐195.
    1. Cereceda‐Monteoliva N, Rouhani MJ, Maughan EF, et al. Sarcoidosis of the ear, nose and throat: a review of the literature. Clin Otolaryngol. 2021;46(5):935‐940. https://doi.org/10.1111/coa.13814
    1. Baughman RP, Grutters JC. New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches. Lancet Respir Med. 2015;3(10):813‐822. https://doi.org/10.1016/S2213-2600(15)00199-X
    1. Rotman A, Maughan EF, Rouhani MJ, et al. Laryngeal sarcoidosis at a tertiary airway centre: our experience with 32 patients. Clin Otolaryngol. 2021;46(2):445‐450. https://doi.org/10.1111/coa.13679
    1. Damsky W, Wang A, Kim DJ, et al. Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis. Nat Commun. 2022;13(1):3140. https://doi.org/10.1038/s41467-022-30615-x

Publication types

LinkOut - more resources